Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.

SELARL PHARMACIE DEGRAVE - DELGRANGE - LUTTUN : revenue, balance sheet and financial ratios

SELARL PHARMACIE DEGRAVE - DELGRANGE - LUTTUN is a French company founded 9 years ago, specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé. Based in HAZEBROUCK (59190), this company of category PME shows in 2025 a net income positive of 444 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - SELARL PHARMACIE DEGRAVE - DELGRANGE - LUTTUN (SIREN 820894566)
Indicator 2025 2024 2023 2022 2021 2020 2019 2018 2017
Revenue N/C N/C N/C N/C N/C N/C N/C N/C N/C
Net income 444 425 € 382 711 € 527 660 € 576 591 € 508 608 € 494 238 € 509 552 € 487 315 € 357 550 €
EBITDA N/C N/C N/C N/C N/C N/C N/C N/C N/C
Net margin N/C N/C N/C N/C N/C N/C N/C N/C N/C

Revenue and income statement

In 2025, SELARL PHARMACIE DEGRAVE - DELGRANGE - LUTTUN generates positive net income of 444 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2017-2025: 358 k€ -> 444 k€.

Net income (2025) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

444 425 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 79%. Debt level is high: negotiating margin with banks is reduced. Financial autonomy (= Equity / Total assets x 100) reaches 52%. This high autonomy means the company finances most of its assets through equity, a sign of strength.

Debt ratio (2025) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

79.464%

Financial autonomy (2025) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

51.54%

Asset age ratio (2025) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

1.2%

Solvency indicators evolution
SELARL PHARMACIE DEGRAVE - DELGRANGE - LUTTUN

Sector positioning

Debt ratio
79.46 2025
2023
2024
2025
Q1: 13.7
Med: 49.79
Q3: 129.09
Average

In 2025, the debt ratio of SELARL PHARMACIE DEGRAVE ... (79.46) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.

Financial autonomy
51.54% 2025
2023
2024
2025
Q1: 33.42%
Med: 53.72%
Q3: 72.08%
Average

In 2025, the financial autonomy of SELARL PHARMACIE DEGRAVE ... (51.5%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 454.20. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2025) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

454.201

Liquidity indicators evolution
SELARL PHARMACIE DEGRAVE - DELGRANGE - LUTTUN

Sector positioning

Liquidity ratio
454.2 2025
2023
2024
2025
Q1: 131.03
Med: 182.25
Q3: 258.64
Excellent

In 2025, the liquidity ratio of SELARL PHARMACIE DEGRAVE ... (454.20) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.

Positioning of SELARL PHARMACIE DEGRAVE - DELGRANGE - LUTTUN in its sector

Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé

Valuation estimate

Based on 277 transactions of similar company sales in 2025, the value of SELARL PHARMACIE DEGRAVE - DELGRANGE - LUTTUN is estimated at 7 059 743 € (range 4 790 775€ - 11 077 710€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2025
277 transactions
4790k€ 7059k€ 11077k€
7 059 743 € Range: 4 790 775€ - 11 077 710€
NAF 5 année 2025

Valuation method used

Net Income Multiple
444 425 € × 15.9x = 7 059 744 €
Range: 4 790 776€ - 11 077 710€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)

Compare SELARL PHARMACIE DEGRAVE - DELGRANGE - LUTTUN with other companies in the same sector:

Voir toutes les statistiques du secteur Commerce de détail de produits pharmaceutiques en magasin spécialisé

Frequently asked questions about SELARL PHARMACIE DEGRAVE - DELGRANGE - LUTTUN

What is the revenue of SELARL PHARMACIE DEGRAVE - DELGRANGE - LUTTUN ?

The revenue of SELARL PHARMACIE DEGRAVE - DELGRANGE - LUTTUN is not publicly disclosed (confidential accounts filed with INPI).

Is SELARL PHARMACIE DEGRAVE - DELGRANGE - LUTTUN profitable?

Yes, SELARL PHARMACIE DEGRAVE - DELGRANGE - LUTTUN generated a net profit of 444 k€ in 2025.

Where is the headquarters of SELARL PHARMACIE DEGRAVE - DELGRANGE - LUTTUN ?

The headquarters of SELARL PHARMACIE DEGRAVE - DELGRANGE - LUTTUN is located in HAZEBROUCK (59190), in the department Nord.

Where to find the tax return of SELARL PHARMACIE DEGRAVE - DELGRANGE - LUTTUN ?

The tax return of SELARL PHARMACIE DEGRAVE - DELGRANGE - LUTTUN is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does SELARL PHARMACIE DEGRAVE - DELGRANGE - LUTTUN operate?

SELARL PHARMACIE DEGRAVE - DELGRANGE - LUTTUN operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.